结肠镜下区分深部黏膜下层浸润与固有肌层浸润结直肠癌的新评分系统:e-T2评分开发与全球多中心外部验证研究
本研究为多中心回顾性交叉验证研究,基于461例病理确诊的T1b或T2结直肠癌,开发并验证了区分T1b与T2的e-T2评分系统。多因素分析确定5项独立预测T2的内镜表现,开发队列AUROC为.90,内部验证为.80,外部验证为.76。
要点
- 5项内镜表现独立预测T2结直肠癌:深凹陷、边界清楚的凹陷区、4条及以上皱襞汇聚、糜烂或白色斑块、Borrmann 2或3型。
- e-T2评分的AUROC在开发队列为.90,内部验证为.80,外部验证为.76。
- 外部验证由日本以外机构的4名内镜医师对50例结直肠癌图像完成。
核心结论
- 研究建立并验证了使用5项简单内镜表现区分T1b与T2结直肠癌的新评分系统。
研究设计与样本
- 多中心回顾性交叉验证研究,纳入461例连续病理确诊的T1b或T2结直肠癌,分为开发队列(T1b 222例、T2 189例)和内部验证队列(T1b 31例、T2 19例)。
- 开发队列评估8项潜在内镜表现;内部验证由8名内镜医师完成;外部验证使用50例结直肠癌图像、由其他机构(包括日本以外)的4名内镜医师完成。
主要发现
- 多因素分析确定5项独立预测T2结直肠癌的内镜表现:深凹陷(OR 2.08;95%CI 1.07-4.04)、边界清楚的凹陷区(OR 4.40;95%CI 1.39-13.9)、4条及以上皱襞汇聚(OR 3.41;95%CI 1.90-6.11)、糜烂或白色斑块(OR 8.28;95%CI 2.77-24.7)、Borrmann 2或3型肿瘤(OR 8.76;95%CI 3.58-21.5)。
- AUROC在开发队列为.90(95%CI .87-.93),内部验证为.80(95%CI .76-.85),外部验证为.76(95%CI .69-.83)。
关键数值与推荐
- 区分T1b与T2结直肠癌的e-T2评分包含5项内镜表现:深凹陷、边界清楚的凹陷区、4条及以上皱襞汇聚、糜烂或白色斑块、Borrmann 2或3型肿瘤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Diagnostics to differentiate deep submucosal invasive (invasion depth ≥1000 μm [T1b]) colorectal cancer (CRC) from muscularis propria invasive (T2) CRC are limited. We aimed to establish and validate a scoring system that differentiates T1b from T2. METHODS: A multicenter retrospective cross-validation study was performed. Four hundred sixty-one consecutive pathologically confirmed T1b or T2 CRCs were divided into the development (T1b, 222; T2, 189) and internal validation (T1b, 31; T2, 19) cohorts. Eight potential endoscopic findings were evaluated using the development cohort: loss of lobulation, deep depression, demarcated depressed area, protuberance within the depression, expanding appearance, fold convergency, erosion or white plaque, and Borrmann type 2 or 3 tumor. A scoring system that differentiates T1b from T2 was developed, and diagnostic performance was tested using the internal validation cohort by 8 endoscopists. External validation was conducted using 50 CRC images by 4 endoscopists from other institutions, including outside of Japan. RESULTS: Multivariate analysis identified the following 5 independent predictive endoscopic findings of T2 CRC: deep depression (odds ratio [OR], 2.08; 95% confidence interval [CI], 1.07-4.04), demarcated depressed area (OR, 4.40; 95% CI, 1.39-13.9), 4-fold convergency or more (OR, 3.41; 95% CI, 1.90-6.11), erosion or white plaque (OR, 8.28; 95% CI, 2.77-24.7), and Borrmann type 2 or 3 tumor (OR, 8.76; 95% CI, 3.58-21.5). The area under the receiver-operating characteristic curve (AUROC) was .90 (95% CI, .87-.93) in the development cohort, .80 (95% CI, .76-.85) in the internal validation, and .76 (95% CI, .69-.83) in the external validation. CONCLUSIONS: We established and validated a new scoring system to differentiate T1b from T2 CRC using 5 simple endoscopic findings.
引用
- Koyama Y, Yamada M, Makiguchi ME, et al. New scoring system to distinguish deep invasive submucosal and muscularis propria colorectal cancer during colonoscopy: a development and global multicenter external validation study (e-T2 Score). Gastrointest Endosc. 2022. PMID: 35271864. doi:10.1016/j.gie.2022.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。